The UK and US have forged a landmark trade agreement that will keep no tariffs on UK medicine exports going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge guarantees that duties on these crucial exports will be held at zero for a period of the next three years.
This development is in response to recent warnings to hike duties on branded drug imports, with increases floated as high as 100%.
"This arrangement between the UK reinforces the international landscape for cutting-edge drugs and establishes long-overdue fairness to American-British drug exports," a release said.
Trade Importance
Drugs are one of the the United Kingdom's biggest goods shipped to the America, which is clearly the largest destination for leading UK drugmakers.
Trade data reveal that in the year to the end of last September, the UK exported medicines worth £11.1bn to the US. This value accounted for a significant portion of total UK exports in that span.
"This deal secures employment, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for life sciences," a government official remarked.
Key NHS Changes
The deal involves several notable commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase overall health service expenditure on treatments from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Recent Tensions
The deal comes amid a ongoing row between the sector and the UK government over medicine costs and NHS adoption.
This friction were heightened by claims that US consumers were charged significantly more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or abandoned, while major investments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the last ten years.
